Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

About Xenon Pharmaceuticals

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company's platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XENE
  • CUSIP:
Key Metrics:
  • Previous Close: $8.15
  • 50 Day Moving Average: $7.97
  • 200 Day Moving Average: $7.25
  • 52-Week Range: $5.65 - $10.07
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.45
  • P/E Growth: -0.52
  • Market Cap: $120.17M
  • Outstanding Shares: 14,426,000
  • Beta: 1.43
Profitability:
  • Net Margins: -199.68%
  • Return on Equity: -28.85%
  • Return on Assets: -27.19%
Debt:
  • Current Ratio: 18.28%
  • Quick Ratio: 18.28%
Additional Links:
Companies Related to Xenon Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Xenon Pharmaceuticals (NASDAQ:XENE) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.33 (105.45% upside)

Analysts' Ratings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016GuggenheimInitiated CoverageBuy -> Buy$20.00View Rating Details
8/5/2016Canaccord GenuityReiterated RatingBuy$16.00View Rating Details
5/11/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details
9/24/2015SEB Equity ResearchReiterated RatingPositiveView Rating Details
12/1/2014Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/3/2016Q216($0.48)($0.42)$2.25 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.65 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.23 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57ViewListenView Earnings Details
12/16/2014$0.41$1.69ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-0.55 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.21)($0.21)($0.21)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.47)($0.47)($0.47)
Q4 20161($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xenon Pharmaceuticals (NASDAQ:XENE)
Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 30.89%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.00View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.12View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
DateHeadline
finance.yahoo.com logoCoverage initiated on Xenon Pharmaceuticals by Guggenheim (NASDAQ:XENE)
finance.yahoo.com - September 26 at 8:08 PM
News IconXenon Pharmaceuticals Announces Closing of $34.5 Million Public Offering (NASDAQ:XENE)
www.bctechnology.com - September 21 at 12:02 PM
News IconXenon pharmaceuticals reports second quarter 2016 financial results and provides corporate update nasdaq_xene data recovery nj (NASDAQ:XENE)
handyrecovery.in - September 19 at 3:15 PM
4-traders.com logoXenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:XENE)
www.4-traders.com - September 17 at 7:32 PM
publicnow.com logoXenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering (NASDAQ:XENE)
www.publicnow.com - September 14 at 12:34 PM
News IconXenon Pharmaceuticals Inc. (XENE): Biotechnology Value Fund Adds More Shares (NASDAQ:XENE)
feedproxy.google.com - September 12 at 1:24 PM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:XENE)
biz.yahoo.com - September 9 at 7:47 PM
streetinsider.com logoXenon Pharmaceuticals (XENE) Prices $30M Common Stock Offering (NASDAQ:XENE)
www.streetinsider.com - September 8 at 12:07 PM
publicnow.com logoXenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of Common Shares (NASDAQ:XENE)
www.publicnow.com - September 8 at 12:07 PM
finance.yahoo.com logo4:33 pm Xenon Pharmaceuticals announces proposed public offering of common shares by existing security holders (NASDAQ:XENE)
finance.yahoo.com - September 7 at 8:16 PM
publicnow.com logoXenon Pharmaceuticals Announces Proposed Public Offering of Common Shares (NASDAQ:XENE)
www.publicnow.com - September 7 at 8:16 PM
capitalcube.com logoXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:XENE)
www.capitalcube.com - August 11 at 11:50 AM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 3-Aug-16 8:30pm GMT (NASDAQ:XENE)
finance.yahoo.com - August 8 at 8:34 PM
benzinga.com logoXenon Expects XEN801 Results In Q1 2017, Delayed One Quarter (NASDAQ:XENE)
www.benzinga.com - August 5 at 11:27 AM
twst.com logoXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:XENE)
www.twst.com - August 5 at 11:27 AM
sg.finance.yahoo.com logoXenon Pharmaceuticals reports 2Q loss (NASDAQ:XENE)
sg.finance.yahoo.com - August 3 at 8:45 PM
biz.yahoo.com logoQ2 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:XENE)
biz.yahoo.com - August 3 at 11:42 AM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:XENE)
finance.yahoo.com - August 2 at 8:46 PM
publicnow.com logoXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update (NASDAQ:XENE)
www.publicnow.com - July 25 at 4:48 PM
publicnow.com logoXenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs at the Jefferies 2016 Healthcare Conference (NASDAQ:XENE)
www.publicnow.com - June 8 at 7:58 AM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:XENE)
biz.yahoo.com - June 3 at 4:32 PM
publicnow.com logoXenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:XENE)
www.publicnow.com - June 2 at 8:25 AM
capitalcube.com logoXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:XENE)
www.capitalcube.com - May 17 at 4:34 PM
sg.finance.yahoo.com logoXenon Pharmaceuticals reports 1Q loss (NASDAQ:XENE)
sg.finance.yahoo.com - May 10 at 5:28 PM
biz.yahoo.com logoXenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:XENE)
biz.yahoo.com - May 10 at 4:30 PM
publicnow.com logoXenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:XENE)
www.publicnow.com - May 10 at 4:18 PM
biz.yahoo.com logoQ1 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:XENE)
biz.yahoo.com - May 10 at 7:07 AM
publicnow.com logoXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update (NASDAQ:XENE)
www.publicnow.com - May 2 at 4:30 PM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 8-Mar-16 9:30pm GMT (NASDAQ:XENE)
finance.yahoo.com - April 7 at 11:41 AM
publicnow.com logoXenon Names Dr. Raymond J. Winquist as Head, Translational Research (NASDAQ:XENE)
www.publicnow.com - April 4 at 5:00 PM
feeds.benzinga.com logoXenon Pharma Will Offer Business, Milestone Update at Needham Conference (NASDAQ:XENE)
feeds.benzinga.com - March 31 at 5:22 PM
publicnow.com logoXenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference (NASDAQ:XENE)
www.publicnow.com - March 31 at 4:55 PM
thestreet.com logoXenon Pharmaceuticals To Host Conference Call And Webcast To Discuss 2015 Financial Results And Provide Corporate Update (NASDAQ:XENE)
www.thestreet.com - March 1 at 9:25 PM
News IconXenon Pharmaceuticals Inc. (XENE) Broker Views - Risers & Fallers (NASDAQ:XENE)
www.risersandfallers.com - February 26 at 1:48 PM
capitalcube.com logoXenon Pharmaceuticals, Inc.: Price momentum supported by strong fundamentals (NASDAQ:XENE)
www.capitalcube.com - February 18 at 4:24 PM
finance.yahoo.com logoXenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne (NASDAQ:XENE)
finance.yahoo.com - February 10 at 8:00 AM
finance.yahoo.com logoXenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery (NASDAQ:XENE)
finance.yahoo.com - February 9 at 8:00 AM
News IconPrice Target Update On Xenon Pharmaceuticals Inc. (XENE) - Risers & Fallers (NASDAQ:XENE)
www.risersandfallers.com - February 2 at 2:45 PM
News IconXenon Pharmaceuticals Inc. (XENE) Recent Analyst Updates - Risers & Fallers (NASDAQ:XENE)
www.risersandfallers.com - January 21 at 1:34 PM
capitalcube.com logoXenon Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:XENE)
www.capitalcube.com - December 23 at 1:08 PM
noodls.com logoXenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain (NASDAQ:XENE)
www.noodls.com - December 17 at 2:43 PM
finance.yahoo.com logoXENON PHARMACEUTICALS INC. Financials (NASDAQ:XENE)
finance.yahoo.com - December 8 at 1:17 PM
insidermonkey.com logoShould You Buy Energy Focus Inc (EFOI)? (NASDAQ:XENE)
www.insidermonkey.com - December 8 at 10:59 AM
noodls.com logoXenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference (NASDAQ:XENE)
www.noodls.com - November 12 at 4:46 PM
biz.yahoo.com logoXenon Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today (NASDAQ:XENE)
biz.yahoo.com - November 10 at 5:00 PM
noodls.com logoXenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update (NASDAQ:XENE)
www.noodls.com - November 10 at 4:56 PM
sg.finance.yahoo.com logoXenon Pharmaceuticals reports 3Q loss (NASDAQ:XENE)
sg.finance.yahoo.com - November 10 at 4:47 PM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:XENE)
biz.yahoo.com - November 10 at 4:32 PM

Social

Xenon Pharmaceuticals (NASDAQ:XENE) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff